Meta Expands AI Training With Employee Activity Tracking Tools 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Inivata to Present at AACR Annual Meeting 2017
Research Triangle Park, NC and Cambridge, UK, April 3, 2017 -- Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, today announces the presentation of new data at the AACR Annual Meeting 2017 in Washington, USA.
The data, entitled "Comparison of enhanced Tagged-Amplicon Sequencing and digital PCR for circulating tumor DNA analysis in advanced breast cancer", will be presented on Monday 3 April from 1:00pm - 5:00pm at the Convention Center. The poster will present the results of a new study showing ctDNA analysis using Inivata's InVisionTM platform and Digital PCR (dPCR) have very a high concordance in mutation detection in patients with advanced breast cancer.
Clive Morris, Chief Medical Officer of Inivata, said, "These results add to our growing body of evidence for the clinical utility of our InVisionTM platform across a number of cancer types. While we have recently announced the results of a first study of the use of a ctDNA liquid biopsy in guiding treatment decisions and delivering better patient outcomes in lung cancer patients, here we explore the utility of ctDNA in breast cancer. These data demonstrate that while our InVision platform has strong concordance with dPCR in breast cancer patients, it also yields more clinically useful biomarker information through a broad panel approach over individual mutational analysis."
About Inivata
Inivata, a clinical cancer genomics company, is employing the precision of ctDNA analysis to improve personalized healthcare in oncology. Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and assess individual response to treatment. Inivata's proprietary technology is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge. Inivata's InVisionTM ctDNA assay provides a highly sensitive analysis of a highly-select gene panel to identify actionable mutations for oncologists to treat their patients optimally. In 2016, Inivata opened a CLIA lab in Research Triangle Park, NC and launched a large-scale, prospective clinical validation study of the Company's ctDNA analysis in lung cancer. For more information and a full listing of investors, please go to www.inivata.com. Follow us on Twitter @Inivata.
Media Contacts:
Consilium Strategic Communications
Chris Gardner/Laura Thornton
[email protected]
+44 (0)20 3709 5700
Karen Chandler-Smith
[email protected]
+44 (0)7900 430235
